[go: up one dir, main page]

HRP20171939T1 - Formulacija protutijela i režimi terapije - Google Patents

Formulacija protutijela i režimi terapije Download PDF

Info

Publication number
HRP20171939T1
HRP20171939T1 HRP20171939TT HRP20171939T HRP20171939T1 HR P20171939 T1 HRP20171939 T1 HR P20171939T1 HR P20171939T T HRP20171939T T HR P20171939TT HR P20171939 T HRP20171939 T HR P20171939T HR P20171939 T1 HRP20171939 T1 HR P20171939T1
Authority
HR
Croatia
Prior art keywords
antibody
seq
heavy chain
light chain
sequence
Prior art date
Application number
HRP20171939TT
Other languages
English (en)
Inventor
Dingjiang Liu
Holly Zhuohong Huang
David Andrew Martin
Christopher Boyd Russell
David H. Salinger
Scott Walter Baumgartner
Christopher J. Endres
Original Assignee
Kirin-Amgen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43858045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171939(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin-Amgen, Inc. filed Critical Kirin-Amgen, Inc.
Publication of HRP20171939T1 publication Critical patent/HRP20171939T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)

Claims (17)

1. Farmaceutska formulacija, koja sadrži vodenu otopinu pufera glutaminske kiseline i protutijela koje sadrži sekvencu varijabilne domene teškog lanca koja obuhvaća SEQ ID NO:3 i sekvencu varijabilne domene lakog lanca koja obuhvaća SEQ ID NO:4, naznačena time da se navedeno protutijelo specifično veže na ljudski receptor A za IL-17, te što: a) navedena formulacija sadrži glutaminsku kiselinu u koncentraciji od 5-30 mM ± 0,2 mM; b) navedena formulacija ima pH 4,5-5,2 ± 0,2; c) navedena formulacija dalje sadrži 2-4% prolin (mas/v) i 0,005-0,02% (mas/v) polisorbat 20; d) navedeno protutijelo ima koncentraciju od 100 do 150 mg/ml.
2. Farmaceutska formulacija prema zahtjevu 1, naznačena time da protutijelo sadrži sekvencu teškog lanca koja obuhvaća SEQ ID NO:1 i sekvencu lakog lanca koja obuhvaća SEQ ID NO:2, ili alternativno, sekvencu teškog lanca koja obuhvaća SEQ ID NO:12 i sekvencu lakog lanca koja obuhvaća sekvencu SEQ ID NO:2.
3. Farmaceutska formulacija prema zahtjevu 1 ili zahtjevu 2, naznačena time da nadalje ima osmolarnost od 250 do 400 mOsm/L.
4. Farmaceutski kontejner, koji obuhvaća posudu i farmaceutsku formulaciju prema bilo kojem od zahtjeva 1 do 3, naznačena time da je navedena posuda bočica, boca, prethodno napunjena injekcija, ili prethodno napunjena autoinjektorska injekcija.
5. Komplet, naznačen time da sadrži jedan ili više farmaceutskih spremnika prema zahtjevu 4 i upute u vezi s njihovom upotrebom.
6. Farmaceutska formulacija prema bilo kojem od zahtjeva 1-3 naznačena time da je za upotrebu u postupku liječenja psorijaze kod humanog pacijenta, pri čemu je protutijelo u dozi od 70, 140, 210 ili 280 mg.
7. Farmaceutska formulacija za upotrebu prema zahtjevu 6, naznačena time da se navedenom pacijentu daje doza od 70 do 280 mg navedenog protutijela svakog tjedna, svaka dva tjedna i/ili svakog mjeseca.
8. Farmaceutska formulacija za upotrebu prema zahtjevu 7, naznačena time da se doza od 140 mg navedenog protutijela daje pacijentima koji imaju tjelesnu masu koja je manja od ili približno jednaka 100 kg, te da se doza od 210 mg navedenog protutijela daje pacijentima koji imaju tjelesnu masu koja je veća od 100 kg.
9. Farmaceutska formulacija za upotrebu prema bilo kojem od zahtjeva 6 do 8, naznačena time da se psorijaza bira iz skupine koja sadrži: a) psorijazu koja dovodi do stvaranja plaka; b) umjerenu psorijazu do psorijaze s ozbiljnim simptomima koja dovodi do stvaranja plaka; c) kroničnu umjerenu psorijazu do psorijaze s ozbiljnim simptomima koja dovodi do stvaranja plaka i navedeni pacijenti su kandidati za sistemsku terapiju ili fototerapiju; i d) kroničnu umjerenu psorijazu do psorijaze s ozbiljnim simptomima koja dovodi do stvaranja plaka i što navedeni pacijenti ne reagiraju na, imaju kontraindikaciju prema, ili su netolerantni na druge sistemske terapije uključujući ciklosporin, metotreksat, i psoralen plus fototerapiju ultraljubičastim-A zračenjem.
10. Farmaceutska formulacija za upotrebu prema bilo kojem od zahtjeva 6 do 9, naznačena time da navedena farmaceutska formulacija sadrži oko 140 mg/ml navedenog protutijela, koje je formulirano s 10 ± 0,2 mM glutaminskom kiselinom, 3 ± 0,2% (mas/v) L-prolinom, 0,01 ± 0,002% (mas/v) polisorbatom 20, pH 4,8 ± 0,2.
11. Farmaceutska formulacija za upotrebu prema bilo kojem od zahtjeva 6-10, naznačena time da se navedena farmaceutska formulacija daje subkutano, intradermalno, intramuskularno, i/ili intravenozno.
12. Farmaceutski pripravak koji sadrži protutijelo od oko 100-150 mg/ml, koje je formulirano s: i) glutaminskom kiselinom u koncentraciji od 10 mM; ii) pH od 4,8 ± 0,2; iii) 3% prolinom (mas/v) i 0,01% (mas/v) polisorbatom 20; pri čemu se navedeno protutijelo bira iz skupine koja sadrži: a) protutijelo koje sadrži sekvencu varijabilne domene teškog lanca koja sadrži SEQ ID NO:3 i sekvencu varijabilne domene lakog lanca koja sadrži SEQ ID NO:4, pri čemu se navedeno protutijelo specifično veže za ljudski receptor A za IL-17; i b) protutijelo koje sadrži sekvencu teškog lanca koja sadrži SEQ ID NO:1 i sekvencu lakog lanca koji sadrži SEQ ID NO:2, ili alternativno, sekvencu teškog lanca koja sadrži SEQ ID NO:12 i sekvencu lakog lanca koja sadrži SEQ ID NO:2, za upotrebu u postupku liječenja psorijaznog artritisa kod humanog pacijenta, pri čemu je protutijelo u dozi od 70, 140, 210 ili 280 mg.
13. Farmaceutski pripravak koji sadrži protutijelo od oko 100-150 mg/ml, koje je formulirano s: i) glutaminskom kiselinom u koncentraciji od 10 mM; ii) pH od 4,8 ± 0,2; iii) 3% prolinom (mas/v) i 0,01% (mas/v) polisorbatom 20; pri čemu se navedeno protutijelo bira iz skupine koja sadrži: a) protutijelo koje sadrži sekvencu varijabilne domene teškog lanca koja sadrži SEQ ID NO:3 i sekvencu varijabilne domene lakog lanca koja sadrži SEQ ID NO:4, pri čemu se navedeno protutijelo specifično veže za ljudski receptor A za IL-17; i b) protutijelo koje sadrži sekvencu teškog lanca koja sadrži SEQ ID NO: 1 i sekvencu lakog lanca koji sadrži SEQ ID NO:2, ili alternativno, sekvencu teškog lanca koja sadrži SEQ ID NO:12 i sekvencu lakog lanca koja sadrži SEQ ID NO:2, za upotrebu u postupku liječenja astme kod humanog pacijenta, što je navedeno protutijelo u dozi od 70, 140, 210 ili 280 mg.
14. Farmaceutski pripravak koji sadrži protutijelo od oko 100-150 mg/ml, koje je formulirano s: i) glutaminskom kiselinom u koncentraciji od 10 mM; ii) pH od 4,8 ± 0,2; iii) 3% prolinom (mas/v) i 0,01% (mas/v) polisorbatom 20; pri čemu se navedeno protutijelo bira iz skupine koja sadrži: a) protutijelo koje sadrži sekvencu varijabilne domene teškog lanca koja sadrži SEQ ID NO:3 i sekvencu varijabilne domene lakog lanca koja sadrži SEQ ID NO:4, pri čemu se navedeno protutijelo specifično veže za ljudski receptor A za IL-17; i b) protutijelo koje sadrži sekvencu teškog lanca koja sadrži SEQ ID NO: 1 i sekvencu lakog lanca koji sadrži SEQ ID NO:2, ili alternativno, sekvencu teškog lanca koja sadrži SEQ ID NO:12 i sekvencu lakog lanca koja sadrži SEQ ID NO:2, za upotrebu u postupku liječenja ankilozirajućeg spondilitisa kod humanog pacijenta, što je navedeno protutijelo u dozi od 70, 140, 210 ili 280 mg.
15. Farmaceutski pripravak koji sadrži protutijelo od oko 100-150 mg/ml, koje je formulirano s: i) glutaminskom kiselinom u koncentraciji od 10 mM; ii) pH od 4,8 ± 0,2; iii) 3% prolinom (mas/v) i 0,01% (mas/v) polisorbatom 20; pri čemu se navedeno protutijelo bira iz skupine koja sadrži: a) protutijelo koje sadrži sekvencu varijabilne domene teškog lanca koja sadrži SEQ ID NO:3 i sekvencu varijabilne domene lakog lanca koja sadrži SEQ ID NO:4, pri čemu se navedeno protutijelo specifično veže za ljudski receptor A za IL-17; i b) protutijelo koje sadrži sekvencu teškog lanca koja sadrži SEQ ID NO: 1 i sekvencu lakog lanca koji sadrži SEQ ID NO:2, ili alternativno, sekvencu teškog lanca koja sadrži SEQ ID NO:12 i sekvencu lakog lanca koja sadrži SEQ ID NO:2, za upotrebu u postupku liječenja multiple skleroze kod humanog pacijenta, što je navedeno protutijelo u dozi od 70, 140, 210 ili 280 mg.
16. Formulacija za upotrebu prema bilo kojem od zahtjeva 12 do 15, naznačena time da navedena farmaceutska formulacija nadalje sadrži oko 140 mg/ml navedenog protutijela i što navedeni lijek ima viskoznost od 5 do 7 cP na 25 stupnjeva C.
17. Formulacija za upotrebu prema bilo kojem od zahtjeva 12 do 16, naznačena time da se farmaceutska formulacija daje subkutano, intradermalno, intramuskularno, i/ili intravenozno.
HRP20171939TT 2010-01-15 2011-01-12 Formulacija protutijela i režimi terapije HRP20171939T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29538710P 2010-01-15 2010-01-15
US42205910P 2010-12-10 2010-12-10
PCT/US2011/020985 WO2011088120A1 (en) 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens
EP11705713.3A EP2523688B1 (en) 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens

Publications (1)

Publication Number Publication Date
HRP20171939T1 true HRP20171939T1 (hr) 2018-03-23

Family

ID=43858045

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171939TT HRP20171939T1 (hr) 2010-01-15 2011-01-12 Formulacija protutijela i režimi terapije

Country Status (38)

Country Link
US (5) US8883151B2 (hr)
EP (3) EP3632466A1 (hr)
JP (2) JP5743234B2 (hr)
KR (1) KR101766936B1 (hr)
CN (1) CN102821787B (hr)
AR (1) AR079903A1 (hr)
AU (3) AU2011205402B2 (hr)
BR (1) BR112012017150B1 (hr)
CA (1) CA2787128C (hr)
CL (1) CL2012001966A1 (hr)
CO (1) CO6640206A2 (hr)
CR (1) CR20120419A (hr)
CY (2) CY1119852T1 (hr)
DK (2) DK2523688T3 (hr)
EA (2) EA031209B9 (hr)
ES (2) ES2652637T3 (hr)
HR (1) HRP20171939T1 (hr)
HU (2) HUE046670T2 (hr)
IL (1) IL220602B (hr)
IN (1) IN2012DN06720A (hr)
LT (2) LT3295957T (hr)
MA (1) MA33989B1 (hr)
MX (1) MX349856B (hr)
MY (1) MY182680A (hr)
NO (1) NO2523688T3 (hr)
NZ (1) NZ601125A (hr)
PE (1) PE20121691A1 (hr)
PH (1) PH12012501364A1 (hr)
PL (2) PL3295957T3 (hr)
PT (2) PT2523688T (hr)
RS (2) RS59743B1 (hr)
SG (2) SG182468A1 (hr)
SI (2) SI2523688T1 (hr)
TN (1) TN2012000335A1 (hr)
TW (1) TWI554282B (hr)
UA (1) UA112288C2 (hr)
WO (1) WO2011088120A1 (hr)
ZA (1) ZA201205167B (hr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
JP6078344B2 (ja) * 2010-02-04 2017-02-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリン製剤
NZ603570A (en) 2010-05-20 2014-12-24 Ablynx Nv Biological materials related to her3
SG188591A1 (en) * 2010-09-22 2013-04-30 Amgen Inc Carrier immunoglobulins and uses thereof
CA2832556A1 (en) * 2011-04-07 2012-10-11 Glaxosmithkline Llc Formulations with reduced viscosity
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
AU2012340621B2 (en) * 2011-11-23 2017-10-12 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
JP6117252B2 (ja) * 2012-03-07 2017-04-19 イーライ リリー アンド カンパニー Ｉｌ−１７抗体製剤
EP2850099B1 (en) 2012-05-14 2017-01-18 Novo Nordisk A/S Stabilised protein solutions
CA2906384A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
SG10201804954UA (en) 2013-03-15 2018-07-30 Amgen Inc Methods for treating psoriasis using an anti-il-23 antibody
CA2944605C (en) * 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
CA2949237C (en) 2014-05-16 2022-08-23 Amgen Inc. Assay for detecting th1 and th2 cell populations
US20170298136A1 (en) * 2014-08-26 2017-10-19 Kirin-Amgen, Inc. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
JP6795397B2 (ja) * 2014-09-10 2020-12-02 日油株式会社 蛋白質吸着抑制剤及び蛋白質吸着抑制方法
PL3226895T3 (pl) 2014-12-03 2020-12-28 Csl Behring Ag Produkt farmaceutyczny o zwiększonej stabilności zawierający immunoglobuliny
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2017049035A1 (en) 2015-09-17 2017-03-23 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
HK1255922A1 (zh) 2015-11-04 2019-09-06 Astrazeneca Ab 二肽基肽酶-4和骨膜素作為嗜酸性粒細胞疾病中嗜酸性粒細胞靶向治療藥物臨床反應的預測因子
MX2018007589A (es) 2015-12-22 2018-11-09 Amgen Inc Ccl20 como indicador de respuesta clinica a antagonistas de il23.
JP6694522B2 (ja) 2016-04-19 2020-05-13 セイジ・エレクトロクロミクス，インコーポレイテッド 透明導電性酸化物層及びバスバーを含むエレクトロクロミックデバイス、ならびにその形成プロセス
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
CA2974531A1 (en) * 2017-07-26 2019-01-26 Michael Giroux Safety anchor and roof vent
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20210277105A1 (en) 2018-07-13 2021-09-09 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
WO2021050563A1 (en) * 2019-09-09 2021-03-18 The Rockefeller University Antibody treatment for lesional tissue of hidradenitis suppurativa
EP4028053A1 (en) 2019-09-11 2022-07-20 Bausch Health Ireland Limited Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody
CN112891530B (zh) * 2020-06-19 2021-08-24 北京东方百泰生物科技股份有限公司 一种抗il-17ra单克隆抗体的注射制剂
US20240216506A1 (en) * 2021-05-12 2024-07-04 Anaptysbio, Inc. Antibody composition
WO2023240071A1 (en) * 2022-06-06 2023-12-14 Fusion Pharmaceuticals Inc. Methods of dosing therapeutic agents

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000835A (en) 1911-06-19 1911-08-15 Stewart A Minnick Calipers.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
AU636608B2 (en) 1989-05-18 1993-05-06 Yeda Research And Development Co. Ltd. Tumor necrosis factor binding protein II, it's purification and antibodies thereto
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
WO1991003553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
EP0433900B1 (en) 1989-12-13 1995-09-20 Yeda Research And Development Company Limited Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2243569A (en) 1990-05-02 1991-11-06 Andrew Langdon Brush with timer
EP0464533B1 (de) 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
WO1992001002A1 (fr) 1990-07-11 1992-01-23 Teijin Limited Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
DK0567566T4 (da) 1991-01-18 2007-10-22 Amgen Inc Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993007863A1 (en) 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
DE69333027T2 (de) 1992-03-30 2004-05-06 Immunex Corp., Seattle Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
DE69327582T2 (de) 1992-04-30 2000-08-03 Amgen Inc., Thousand Oaks Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
EP0620739A4 (en) 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
ATE279517T1 (de) 1995-03-23 2004-10-15 Immunex Corp Il-17 receptor
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
WO1997004097A2 (en) 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
AU7408998A (en) 1996-11-27 1998-06-22 Immunex Corporation Method of regulating nitric oxide production
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
WO1999060127A2 (en) 1998-05-15 1999-11-25 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
WO1999014240A1 (en) 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
PT1491208E (pt) 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Composições farmacêuticas contendo polipéptido líquidas estabilizadas
MXPA02009055A (es) 2000-03-16 2003-03-12 Amgen Inc Receptor il-17 como moleculas y usos de los mismos.
AR030554A1 (es) 2000-03-16 2003-08-27 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
US20030180255A1 (en) 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6793919B2 (en) 2000-10-18 2004-09-21 Immunex Corporation Methods for treating rheumatoid arthritis using IL-17 antagonists
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
WO2004002519A1 (en) 2002-06-27 2004-01-08 Smithkline Beecham Corporation Methods of treating or preventing ibd with il-18
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
JP2007501252A (ja) 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調整剤を含有する製剤
GB0321703D0 (en) * 2003-09-16 2003-10-15 Imerys Minerals Ltd Surface modified fillers for polymer resin compositions
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
IL159670A0 (en) 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
KR20070085199A (ko) 2004-06-04 2007-08-27 디자이너 몰레큘스 인코퍼레이티드 자유-라디칼에 경화되는 폴리에스테르 및 그 사용 방법
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
MX2007009810A (es) 2005-02-14 2008-03-07 Wyeth Corp Uso de interleucina-17f en diagnostico y terapia de inflamacion de vias aereas.
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
EP1917030A4 (en) 2005-08-03 2011-03-09 Immunogen Inc IMMUNKONJUGATFORMULIERUNGEN
CA2915270C (en) 2005-08-05 2017-07-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US20080199460A1 (en) 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
CA2624763A1 (en) 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
EP3593790A1 (en) 2005-11-01 2020-01-15 Wyeth LLC Sodium chloride solution for drug reconstitution or dilution
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CN101541833B (zh) * 2006-10-02 2014-01-29 麒麟-安姆根有限公司 Il-17受体a抗原结合蛋白质
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
WO2008049070A2 (en) 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
EP2129401B8 (en) * 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
FR2910324B1 (fr) 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CA2679588A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
AU2008266948B2 (en) * 2007-06-13 2012-08-23 Kirin-Amgen, Inc. IL-17 heteromeric receptor complex
US20110014676A1 (en) 2007-06-29 2011-01-20 Battelle Memorial Institute Protein stabilization
CA2696049A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
WO2009136976A2 (en) 2008-02-21 2009-11-12 Amgen Inc Il-17ra-il-17rb antagonists and uses thereof
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
PH12012501364A1 (en) * 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
RU2591083C2 (ru) 2010-10-08 2016-07-10 Новартис Аг Способы лечения псориаза с использованием антагонистов il-17
WO2012061129A1 (en) 2010-10-25 2012-05-10 Genentech, Inc Treatment of gastrointestinal inflammation and psoriasis a
CN103582724A (zh) * 2011-04-07 2014-02-12 葛兰素史密斯克莱有限责任公司 粘度降低的制剂
CA2832556A1 (en) * 2011-04-07 2012-10-11 Glaxosmithkline Llc Formulations with reduced viscosity
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CA2944605C (en) 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
US20170298136A1 (en) 2014-08-26 2017-10-19 Kirin-Amgen, Inc. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy

Also Published As

Publication number Publication date
SI2523688T1 (en) 2018-03-30
US20130022621A1 (en) 2013-01-24
EA031209B1 (ru) 2018-12-28
KR101766936B1 (ko) 2017-08-09
PT3295957T (pt) 2019-11-12
AR079903A1 (es) 2012-02-29
PL2523688T3 (pl) 2018-04-30
EP3295957A1 (en) 2018-03-21
CO6640206A2 (es) 2013-03-22
AU2011205402B2 (en) 2015-02-05
US11505612B2 (en) 2022-11-22
EP2523688A1 (en) 2012-11-21
NO2523688T3 (hr) 2018-03-10
PL3295957T3 (pl) 2020-03-31
IN2012DN06720A (hr) 2015-10-23
PE20121691A1 (es) 2012-12-14
CN102821787A (zh) 2012-12-12
BR112012017150A2 (pt) 2017-10-10
KR20120118036A (ko) 2012-10-25
EA201891433A2 (ru) 2018-11-30
US20200399384A1 (en) 2020-12-24
WO2011088120A8 (en) 2012-09-13
MY182680A (en) 2021-01-29
AU2011205402A1 (en) 2012-07-12
CR20120419A (es) 2012-11-29
PH12012501364A1 (en) 2012-10-22
CN102821787B (zh) 2015-07-29
EP2523688B1 (en) 2017-10-11
MX2012008213A (es) 2012-11-06
US20180346583A1 (en) 2018-12-06
CY1122466T1 (el) 2020-10-14
SG10201604093XA (en) 2016-07-28
CY1119852T1 (el) 2018-06-27
ES2652637T3 (es) 2018-02-05
US8883151B2 (en) 2014-11-11
US10808033B2 (en) 2020-10-20
EA201891433A3 (ru) 2019-02-28
TW201129382A (en) 2011-09-01
NZ601125A (en) 2014-08-29
BR112012017150B1 (pt) 2022-03-03
ES2753216T3 (es) 2020-04-07
WO2011088120A9 (en) 2012-08-09
AU2017216579A1 (en) 2017-09-07
HUE035618T2 (en) 2018-05-28
TN2012000335A1 (en) 2013-12-12
US20150017184A1 (en) 2015-01-15
SG182468A1 (en) 2012-08-30
DK3295957T3 (da) 2019-10-14
CA2787128A1 (en) 2011-07-21
RS59743B1 (sr) 2020-02-28
US10072085B2 (en) 2018-09-11
JP2013517277A (ja) 2013-05-16
US20230192873A1 (en) 2023-06-22
PT2523688T (pt) 2018-01-05
EA201290653A1 (ru) 2013-02-28
MA33989B1 (fr) 2013-02-01
EA031209B9 (ru) 2021-11-19
EP3632466A1 (en) 2020-04-08
RS56781B1 (sr) 2018-04-30
CA2787128C (en) 2019-06-11
LT3295957T (lt) 2020-01-27
JP5743234B2 (ja) 2015-07-01
ZA201205167B (en) 2013-03-27
AU2015202023B2 (en) 2017-05-18
JP2015052017A (ja) 2015-03-19
TWI554282B (zh) 2016-10-21
CL2012001966A1 (es) 2013-01-18
EP3295957B1 (en) 2019-08-07
SI3295957T1 (sl) 2020-02-28
HUE046670T2 (hu) 2020-03-30
MX349856B (es) 2017-08-16
WO2011088120A1 (en) 2011-07-21
DK2523688T3 (en) 2017-12-04
LT2523688T (lt) 2018-03-12
IL220602B (en) 2019-03-31
AU2015202023A1 (en) 2015-05-14
UA112288C2 (uk) 2016-08-25

Similar Documents

Publication Publication Date Title
HRP20171939T1 (hr) Formulacija protutijela i režimi terapije
HRP20231282T1 (hr) Stabilna formulacija antitijela
BR112014008551A2 (pt) conjunto de válvulas para uso com recipiente de líquido e frasco de medicamento
JP2017031213A5 (hr)
AR109494A1 (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
IL291556B1 (en) Methods and compositions for cns delivery of arylsulfatase a
BR112012022223A8 (pt) Formulação de proteína concentrada, uso e método de preparação da mesma
HRP20211660T1 (hr) Postupci i pripravci za dostavu aril-sulfataze-a u središnji živčani sustav
RS52471B (en) DOSAGE MODES FOR TREATMENT OF TRAUMATIC BRAIN INJURY BY PROGESTERON
ES2521565T3 (es) Composiciones y métodos para el tratamiento de la esclerosis múltiple
JP2021193121A (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
ES2706059T3 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y derivado de L-arginina y una inyección que incluye la composición
PE20050438A1 (es) Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
HRP20240082T1 (hr) Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
RU2014127298A (ru) Применения иммуноконъюгатов, мишенью которых является cd138
JP2011527301A5 (hr)
CL2011001178A1 (es) Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
HRP20161221T1 (hr) Tr1 stanice za liječenje artritičnih stanja
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
RU2015119603A (ru) Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc
CY1113683T1 (el) Συστημα συσκευασιας για φαρμακευτικες συνθεσεις και kit για ενδοφλεβια χορηγηση
JP2020527540A5 (hr)
Gopalakrishna et al. Long-acting injectable aripiprazole: how might it fit in our tool box?
JP2021517144A (ja) Ｃｄ４７遮断療法およびｃｄ３８抗体の組み合わせ
JP2006508977A5 (hr)